Valneva SE is a European biotechnology company specializing in vaccine development and production. The company focuses on developing promising prophylactic vaccines aimed at combating infectious disea... Valneva SE is a European biotechnology company specializing in vaccine development and production. The company focuses on developing promising prophylactic vaccines aimed at combating infectious diseases with significant unmet medical needs. Valneva SE's innovative approach leverages advanced research technologies to create vaccines across various infectious areas, including chikungunya, Lyme disease, and COVID-19. One of its notable vaccine candidates is the inactivated SARS-CoV-2 vaccine, developed in partnership with other leading pharmaceutical entities to enhance global vaccination efforts.
Valneva SE primarily impacts the healthcare and biotechnology sectors, contributing significantly to public health through its pipeline of vaccines and ongoing research. In the financial market, it plays a crucial role in addressing the demand for new and effective vaccines as pathogens evolve and new infectious diseases emerge. Headquartered in Saint-Herblain, France, Valneva SE is a key player in responding to global health challenges, reflecting its importance in the international healthcare landscape.
Pending data availability
Energy Management Data missing for Valneva
We haven’t collected Energy Management data for Valneva yet, or the company
hasn’t made it publicly available.